CRISPR-Cas13a Lateral Flow Assay for Sensitive Nucleic Acid Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nucleic acid detection methods, such as PCR-based tests, are costly, time-consuming, and require sophisticated equipment and skilled personnel, limiting their effectiveness for rapid and widespread detection of pathogens like SARS-CoV-2, especially in resource-limited settings and during pandemics.
Innovation Solution
A nucleic acid detection platform using chimeric fusions between CRISPR enzymes and relaxases, specifically Cas9 variants, for specific binding to target sequences and ssDNA probes, enabling a low-cost, sensitive, and specific lateral flow assay for COVID-19 and other pathogen detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If PCR-based testing is used for nucleic acid detection, then detection sensitivity and specificity are improved, but cost, turnaround time, and equipment requirements increase
Solution Approach 1:
The patent replaces complex PCR-based mechanical and thermal cycling systems with a CRISPR-Cas13a enzymatic reaction system that operates under isothermal conditions. The Cas13a enzyme, guided by sgRNA, specifically binds to viral RNA targets and activates collateral cleavage activity that cuts reporter molecules, generating detectable signals without requiring thermal cyclers or complex instrumentation.
Solution Approach 2:
The patent introduces CRISPR-Cas13a as an intermediary between the viral RNA target and the detection signal. The Cas13a enzyme serves as a molecular mediator that recognizes specific viral sequences through sgRNA guidance and translates this recognition into detectable collateral cleavage signals by cutting reporter molecules, thereby enabling sensitive detection without direct PCR amplification.
2Measurement precision
If PCR-based testing is used for nucleic acid detection, then detection sensitivity and specificity are improved, but turnaround time increases
Solution Approach 1:
The patent employs isothermal amplification methods such as RPA (Recombinase Polymerase Amplification) or LAMP (Loop-mediated Isothermal Amplification) that perform repeated cycles of DNA synthesis at a constant temperature rather than requiring periodic heating and cooling cycles. This continuous amplification at constant temperature significantly reduces the time required while maintaining sensitivity, as the enzymatic reactions proceed continuously without thermal cycling delays.
3Measurement precision
If PCR-based testing is used for nucleic acid detection, then detection sensitivity is improved, but cost increases
Solution Approach 1:
The patent utilizes inexpensive, easily synthesized components including CRISPR guide RNAs (sgRNA), small molecular weight reporters (such as fluorescent dyes or colorimetric substrates), and commercially available Cas13a enzymes. These components can be produced at low cost through standard biochemical synthesis methods, making the overall test significantly cheaper than PCR while maintaining comparable or superior sensitivity through the highly specific CRISPR recognition mechanism.
4Loss of time
If LFA is used for rapid detection, then turnaround time is reduced, but detection sensitivity and specificity decrease
Solution Approach 1:
The patent merges two previously separate processes into a unified isothermal system: (1) target amplification via RPA or LAMP at constant temperature, and (2) CRISPR-Cas13a mediated detection also at the same temperature. This merging eliminates the need for separate thermal cycling equipment and allows both amplification and detection to occur simultaneously in one reaction tube, achieving rapid turnaround without sacrificing sensitivity.
Solution Approach 2:
The patent replaces the traditional LFA immunological binding mechanism with a CRISPR-based molecular recognition system. Instead of relying on antibody-antigen binding which has limited specificity, the system uses programmable CRISPR-Cas13a RNA-guided nucleic acid recognition that provides sequence-specific detection with much higher precision, while maintaining the rapid, equipment-free format of lateral flow assays.
5Device complexity
If LFA is used for nucleic acid detection, then equipment requirements are reduced, but false positives increase due to primer dimers
Solution Approach 1:
The patent introduces CRISPR-Cas13a as a selective intermediary that specifically recognizes and binds only to the intended viral RNA target sequences through programmable sgRNA. This intermediary layer filters out false positive signals from primer dimers or non-specific amplification products, as the Cas13a enzyme will only activate collateral cleavage when bound to the correct target sequence, thereby greatly improving reliability while maintaining equipment simplicity.
Solution Approach 2:
The system employs a feedback mechanism where the CRISPR-Cas13a complex monitors the amplification products in real-time. When primer dimers or non-specific products are generated, the Cas13a enzyme does not bind to them and thus does not activate collateral cleavage, providing negative feedback that prevents false positive signals. Only correct target sequences trigger the positive feedback loop of enzyme activation and signal amplification.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platform provides a rapid, sensitive, and specific modality for COVID-19 detection, capable of identifying viral RNA in a single step, with reduced false positives and no need for expensive reagents, making it suitable for point-of-care testing and large-scale deployment.
Implementation Method 1
CRISPR systems have been harnessed for diagnostics. CRISPR-Dx relies on the ability of the CRISPR system to scan the nucleic acid and find a complementary sequence to the single-guide RNA (sgRNA) of the CRISPR complex
Implementation Method 2
Lateral flow assays (LFAs) have played critical roles in diagnostics
Implementation Method 3
Lateral flow assays (LFAs) have played critical roles in diagnostics but the extraordinary potential LFAs has not yet been fully exploited for widespread use in the detection of different analytes from diverse sources
Data Source
AI summary
Rapid, sensitive, and specific point-of-care testing for pathogens is crucial for disease control. Lateral flow assays (LFAs) have been employed for nucleic acid detection, but they have limited sensitivity and specificity. A fusion of catalytically inactive Cas9 endonuclease and a relaxase for example, VirD2 are used for sensitive, specific nucleic acid detection by LFA. VirD2-dCas9 specifically binds the target nucleic acid sequence via dCas9 and covalently binds to a FAM-tagged oligonucleotide via VirD2. The biotin label and FAM tag are detected using a LFA. This system, termed Vigilant (VirD2-dCas9 guided and LFA-coupled nucleic acid test) is coupled to reverse transcription-recombinase polymerase amplification to detect pathogenic nucleic acid of interest in a sample, it exhibits an impressive limit of detection and shows no cross-reactivity, thus reducing incidents of false positives. Vigilant offers an easy-to-use, rapid, cost-effective, and robust detection platform for SARS-CoV2.